Dentsply Sirona (XRAY) Q2 2026 Earnings Call Transcript

Dentsply Sirona reported Q2 revenue of $898M (-4.1% reported; -6.3% constant currency) and adjusted EPS of $0.52, flat YoY, but supported by $44M of tariff refunds (+$0.17/share). Operating cash flow rose to $99M vs. $48M last year, while the company repurchased 1.3M shares for ~$12M; net debt/EBITDA was 3.2x. Full-year 2026 guidance was maintained ($3.5B–$3.6B revenue; adj. EPS $1.40–$1.50 excluding tariff/refund effects), and Q3 revenue is expected to decline sequentially with earnings below Q2 levels (excluding refund benefits), reflecting an ongoing turnaround.

Analysis

This is still a recovery story, not a clean fundamental inflection. The market should discount the quarter’s cash generation because it was materially assisted by one-offs and working-capital actions; the more important signal is that management is choosing to spend into the turnaround before revenue evidence shows up. That usually keeps near-term multiple expansion capped, because investors are paying for a 2027 earnings bridge while the P&L remains noisy over the next 1-2 quarters.

The real swing factor is channel normalization in Europe and whether the U.S. salesforce reset actually improves sell-through rather than just sell-in. If dealer inventories keep falling, reported growth can look weak even as end demand stabilizes, which creates a setup for a mechanical Q4 bounce but not necessarily durable outperformance. Competitive pressure is quietly shifting toward lower-cost digital and value implant solutions; that tends to compress mix and makes the premium/orthodontic pieces of the portfolio the most vulnerable if the consumer or elective-procedure backdrop softens.

Contrarian takeaway: consensus may be giving too much credit to the turnaround cadence. A rep build, distributor expansion, and digital platform adoption can all help, but those are multi-quarter to multi-year levers, and management itself is telegraphing that the P&L benefit is back-half weighted and likely more visible in 2027 than 2026. The thesis is falsified if U.S. organic growth turns positive in Q4 without another inventory drag, or if EMEA sell-through re-accelerates enough to prove the current weakness was purely channel, not demand.

Key Decisions for Investors

• Sell strength in XRAY over the next 1-3 weeks; treat the stock as a show-me turnaround and fade rallies that price in a Q4 inflection before channel data confirms it. Cover if Q3 exits with positive U.S. growth or if Q4 guidance is raised on real sell-through, not inventory replenishment.
• Use a 3-6 month bearish options structure on XRAY (put spread rather than outright puts) to express the view that near-term upside is capped while the company still absorbs tariff/freight and reinvestment drag. The spread should profit if the market re-rates the story back to a slower 2027 repair path.
• If you want a relative-value expression, pair long a higher-quality dental/digital franchise such as ALGN against short XRAY to isolate secular digital adoption from execution risk. This works best if low-cost scanner competition and aligner price pressure remain the dominant industry narrative over the next 2 quarters.
• Set an alert on two falsifiers: 1) positive U.S. organic growth in Q4 2026, and 2) EDS/implant sell-through recovering without another dealer inventory reduction. Either would argue the turnaround is starting earlier than the market expects.